Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521113 | 0.93 | HRH3 (0.71) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL27853347 | 0.92 | HRH3 (0.78) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL20236316 | 0.90 | LTA4H (0.71) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL519633 | 0.88 | LTA4H (0.91) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL28180293 | 0.87 | LTA4H (0.71) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL4992188 | 0.87 | LTA4H (0.89) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL16569908 | 0.86 | LTA4H (0.66) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL9471555 | 0.85 | DRD3 (0.70) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL3866515 | 0.85 | LTA4H (0.67) | LTA4HPTGS2PTGS1ALDH1A1KDM4E | |
| SCHEMBL519451 | 0.84 | LTA4H (0.71) | LTA4HPTGS2PTGS1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111566100-B | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3040329-B1 | AROMATIC COMPOUND AND USE THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH BONE METABOLISM | KYOTO PHARMA IND (JP) | 2018-10-10 | — | — | EP | disclosed |
| US-10059663-B2 | Aromatic compound and use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | SOST, BMP2, ALPI | LTA4H 3792/4885PTGS2 4609/4885PTGS1 3850/4885 |
| US-10059663-B2 | Aromatic compound and use thereof | SOST, ALPI, FGF23 | LTA4H 3941/4885PTGS2 4444/4885PTGS1 3525/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | LTA4H 1682/4885PTGS2 1462/4885PTGS1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.